- Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
- Coherus Presents Data from Next-generation Immuno-oncology Programs
- Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline
- Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002
- EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06
- Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201
- HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy
- Immutep Announces New Biomarker Data from TACTI-002 Phase II in 1L NSCLC
- Medigene presents new data for MDG2011 demonstrating capability to generate TCR-T therapies against mKRAS
- MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors
- RAPT Therapeutics Announces Positive ORR and PFS Data from Phase 2 Trial of FLX475 + Checkpoint Inhibitor in Patients with Advanced NSCLC
- Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and HCT Recipients with Skin Cancers
- Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101